Answers are grounded in this paper and cite their sources.
// Koichi Takahashi 1, 3, 4 , Keyur Patel 2 , Carlos Bueso-Ramos 2 , Jianhua Zhang 3 , Curtis Gumbs 3 , Elias Jabbour 1 , Tapan Kadia 1 , Michael Andreff 1 , Marina Konopleva 1 , Courtney DiNardo 1 , Naval Daver 1 , Jorge Cortes 1 , Zeev Estrov 1 , Andrew Futreal 3 , Hagop Kantarjian 1 , Guillermo Garcia-Manero 1 1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan Correspondence to: Guillermo Garcia-Manero, e-mail: ggarciam@mdanderson.org Keywords: TP53, myelodysplastic syndromes, hypomethylating agents Received: October 17, 2015 Accepted: January 09, 2016 Published: February 9, 2016 ABSTRACT We screened TP53 mutations in 168 MDS patients who were treated with HMA and evaluated predictive and prognostic value of TP53 mutations. Overall response to HMA was not different based on TP53 mutation status (45% vs. 32% in TP53 -mutated and wild type [WT], respectively, P = 0.13). However, response duration was significantly shorter in TP53 -mutated patients compared to WT patients (5.7 months vs. 28.5 months, P = 0.003). Longitudinal analysis of TP53 mutations after HMA showed that TP53 mutations almost always persisted at times of disease progression. TP53 -mutated patients showed significantly worse overall survival (OS) compared to WT patients (9.4 months vs. 20.7 months, P <0.001). Further, TP53 mutations distinguished prognosis in the subgroup of patients with complex karyotype and Revised International Prognostic Scoring System (IPSS-R) defined very high-risk disease. Multivariate analysis showed that TP53 mutation status is significantly prognostic for OS after adjusting prognostic effect from other factors. The current study provides evidence that TP53 mutations are independently prognostic in MDS patients treated with HMA. While TP53 -mutated MDS patients initially respond well to HMA, their duration of response is significantly shorter than WT patients. Novel strategies to improve duration of response in TP53- mutated MDS are urgently needed.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: